Advanced Issue Resolution in Safety Pharmacology - 1st Edition - ISBN: 9780128122068, 9780128123348

Advanced Issue Resolution in Safety Pharmacology

1st Edition

Editors: Mary Kallman Michael Pugsley
eBook ISBN: 9780128123348
Hardcover ISBN: 9780128122068
Imprint: Academic Press
Published Date: 7th September 2018
Page Count: 360
Sales tax will be calculated at check-out Price includes VAT/GST
245.41
208.60
175.00
148.75
155.00
131.75
135.00
114.75
Unavailable
Price includes VAT/GST

Institutional Subscription

Secure Checkout

Personal information is secured with SSL technology.

Free Shipping

Free global shipping
No minimum order.

Description

Advanced Issue Resolution in Safety Pharmacology not only discusses unique issues that may emerge during the development of new medicines, but also provides detailed insights on how to resolve them. The book employs a valuable strategy that integrates preclinical findings with the clinical resolution of those findings. In addition, it introduces key interdisciplinary topics in an accessible and systematic format. Edited and written by leaders in the field of safety pharmacology, this book considerably advances the discussion on issue resolution topics, thus raising them to the next level of importance by providing scientists with an indispensable resource on solving safety issues.

Key Features

  • Focuses on pharmacology issues that result during drug development and provides de-risking techniques and practical advice
  • Covers a broad selection of topics, including specialized animal models, PBPK modeling, the use of high frequency EEG in problem-solving, drug-induced self-injury, abuse potential liability, biomarkers, imaging, and much more
  • Focuses on the resolution of these issues in order to better address regulatory expectancies and develop safer, more effective drugs

Readership

Individuals interested in safety aspects of drug discovery and development including safety pharmacologists, nonclinical toxicologists, pharmacologists, clinicians, regulatory agency scientists, and academics (including graduate students and post-doctoral fellows) in medical sciences programs in these same areas

Table of Contents

1. Introduction to Issue Resolution

2. Selection of Nontraditional Species for Issue Resolution Studies

3. The Use of Modeling to Facilitate Decision-Making in Safety Pharmacology Assessments

4. Issue Resolution of Drug-Induced Breathing Instability and the Occurrence of Apneic Events

5. The Impact of Drug-Induced Effects on the Gastrointestinal System: Challenges and Issue Resolution for Safety Pharmacology

6. Sleep and Sleep Disruption

7. Self-Injurious Behavior in Clinical and Preclinical Populations: Description, Etiology, and Management

8. Approaches for Early Identification of Abuse Potential Liability

9. Issue Resolution of Motor Deficits and Stereotypies

10. Issue Resolution Related to Convulsive Profiles

11. Utility of Progressive Ratio Schedules of Reinforcement in Abuse Potential Assessments

12. Application of Imaging in the Resolution of Safety Pharmacology Issues

13. Cardiovascular Safety Pharmacology Issue Resolution

14. Use of In Vitro Models in Drug Development and Issue Resolution

15. Future Needs in Issue Resolution of Problems That Arise in Drug Development

 

Details

No. of pages:
360
Language:
English
Copyright:
© Academic Press 2019
Published:
Imprint:
Academic Press
eBook ISBN:
9780128123348
Hardcover ISBN:
9780128122068

About the Editor

Mary Kallman

Dr. Kallman worked for Lilly Research Labs for 17 years as Group Leader for Safety Pharmacology and for Covance Laboratories, a large CRO, for 7 years as Director of Global Nonclinical Neuroscience. She retired from Covance in May of 2015 and she is currently managing a consulting business which provides input on CNS issue resolution and drug abuse liability strategies for drugs in development. She is past president of the Safety Pharmacology Society, past president for the Scientific Liaison Coalition of the Society of Toxicology and co-leader of the industry Cross Company Abuse Liability Consortium. She frequently publishes and presents on preclinical abuse liability issues and previously held National Institute of Drug Abuse RO1 grants on various abuse liability issues.

Affiliations and Expertise

CEO, Kallman Preclinical Consulting

Michael Pugsley

Dr. Pugsley currently works for Purdue Pharma LP as Director of Toxicology and PKDM. Prior to this he worked for Johnson & Johnson in the Drug Safety Sciences group conducting early discovery and IND-enabling Toxicology studies as well as Safety Pharmacology core battery studies for multiple therapeutic areas. Prior to this he was a Senior Principal Scientist at Forest Laboratories, Jersey City, NJ where he worked on a wide array of drugs that are currently used clinically such as Benicar for hypertension. Prior to his position at Forest, he worked at a biotechnology company called XOMA (US) LLC, in Berkeley, CA where he conducted in vivo and in vitro efficacy and safety pharmacology studies on a wide array of biologics for many therapeutic areas. He is currently the President of the Safety Pharmacology Society and has recently published a book entitled ‘Principles of Safety Pharmacology’. He has also authored multiple reviews and published numerous scientific articles on safety pharmacology and serves on the editorial board of several pharmacology journals.

Affiliations and Expertise

Director of Toxicology and PKDM, Purdue Pharma LP

Ratings and Reviews